How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
Site-directed Mutagenesis Kit Market
- By Kit Type: PCR-based Site-directed Mutagenesis Kits, Oligonucleotide-directed Mutagenesis Kits, Enzyme-based Mutagenesis Kits, CRISPR-based Mutagenesis Kits, Chemical Mutagenesis Kits
- By End User: Academic and Research Institutes, Pharmaceutical and Biotechnology Companies, Contract Research Organizations (CROs), Clinical and Diagnostic Laboratories
- By Application: Gene Function Analysis, Protein Engineering, Drug Development, Genetic Disease Research, Agricultural Biotechnology
- By Product Format: Ready-to-use Kits, Customizable Kits, Bulk Reagents
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - PCR-based Site-directed Mutagenesis Kits leads By Kit Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 15 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
11 chapters · 274 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.63 →
- 10 Competitive Landscape 5 sections p.165 →
- 11 Company Profiles 15 players: SWOT & benchmarking p.173 →
Full report · locked preview
Everything inside the Site-directed Mutagenesis Kit Market report
A complete, evidence-based study - 11 chapters and 115 sections covering market size, segmentation across 4 axes, regional analysis and 15 company profiles, forecast to 2033.
Segmentation covered
Kit Type 5
End User 4
Application 5
Product Format 3
Companies profiled
Thermo Fisher Scientific
New England Biolabs
Agilent Technologies
Takara Bio Inc.
Qiagen
Promega Corporation
Bio-Rad Laboratories
Sigma-Aldrich (Merck Group)
NEB (New England Biolabs)
Clontech Laboratories (Takara Bio)
Stratagene (Agilent Technologies)
GenScript
+3 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
15 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Thermo Fisher Scientific
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →New England Biolabs
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Agilent Technologies
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Takara Bio Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Qiagen
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Promega Corporation
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →Bio-Rad Laboratories
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.191 →Sigma-Aldrich (Merck Group)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →NEB (New England Biolabs)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Clontech Laboratories (Takara Bio)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →Stratagene (Agilent Technologies)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →GenScript
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →Zymo Research
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →Lucigen Corporation
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →Epoch Life Science
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$7,022M by 2033 · 10.3% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- PCR-based Site-directed Mutagenesis Kits51.1
- Oligonucleotide-directed Mutagenesis Kits14.5
- Enzyme-based Mutagenesis Kits8.3
- CRISPR-based Mutagenesis Kits18.4
- Chemical Mutagenesis Kits7.8
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$1,058M → $2,540M · 11.6%
Europe$737.2M → $1,743M · 11.4%
Asia Pacific$673.1M → $1,358M · 9.2%
Latin America$416.7M → $888.6M · 9.9%
Middle East and Africa$320.5M → $632.4M · 8.9%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →10.262026
10.262027
10.272028
10.292029
10.312030
10.312031
10.322032
10.332033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Thermo Fisher Scientific19.9
- New England Biolabs18.0
- Agilent Technologies14.7
- Takara Bio Inc.6.3
- Qiagen7.4
- Promega Corporation5.7
- Others28.0
Segment contribution to growth (%)
Fig. 18 · p.39 →Kit Type20.1%
End User34.8%
Application19.0%
Product Format26.1%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America35.5
- Europe24.3
- Asia Pacific19.0
- Latin America12.4
- Middle East and Africa8.8
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Thermo Fisher Scientific | 91 | 77 | 75 | 79 | 88 | 74 | 81 |
| New England Biolabs | 73 | 92 | 90 | 82 | 77 | 86 | 83 |
| Agilent Technologies | 82 | 67 | 81 | 74 | 72 | 63 | 73 |
| Takara Bio Inc. | 74 | 66 | 64 | 78 | 71 | 81 | 72 |
| Qiagen | 57 | 68 | 55 | 62 | 77 | 65 | 64 |
| Promega Corporation | 57 | 52 | 66 | 63 | 48 | 62 | 58 |
| Bio-Rad Laboratories | 51 | 64 | 40 | 54 | 46 | 63 | 53 |
| Sigma-Aldrich (Merck Group) | 58 | 39 | 53 | 48 | 54 | 36 | 48 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Thermo Fisher Scientific
- New England Biolabs
- Agilent Technologies
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Thermo Fisher Scientific | ✓ | ✓ | ◐ | ◐ | ◐ | ◐ |
| New England Biolabs | ◐ | ✓ | ✓ | ◐ | ✓ | ◐ |
| Agilent Technologies | ✓ | ◐ | ◐ | ◐ | − | ✓ |
| Takara Bio Inc. | ✓ | ◐ | − | ✓ | − | ◐ |
| Qiagen | ◐ | ◐ | − | ◐ | ✓ | ◐ |
| Promega Corporation | − | − | ✓ | ◐ | − | − |
| Bio-Rad Laboratories | ◐ | − | ◐ | − | − | ◐ |
| Sigma-Aldrich (Merck Group) | − | − | − | − | ◐ | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1New England Biolabs83
2Thermo Fisher Scientific81
3Agilent Technologies73
4Takara Bio Inc.72
5Qiagen64
6Promega Corporation58
7Bio-Rad Laboratories53
8Sigma-Aldrich (Merck Group)48
Competitive tiers
§8.4 · p.172 →Leader2
Set the pace on share, breadth and innovation.
Thermo Fisher ScientificNew England Biolabs
Challenger2
Strong scale, closing on the leaders.
Agilent TechnologiesTakara Bio Inc.
Contender2
Focused players with pockets of strength.
QiagenPromega Corporation
Niche2
Specialists in a single segment or region.
Bio-Rad LaboratoriesSigma-Aldrich (Merck Group)
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Kit Type in North America, then scale across Site-directed Mutagenesis Kit Market — a $445M beachhead inside a $7.18B market.
Beachhead (SOM)$445Mobtainable near-term
Serviceable (SAM)$2.84Breachable market
Primary motionPartner-led + digitalgo-to-market
Time to scale3 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion87 fit
PCR-based Site-directed Mutagenesis Kits
Best fit — highest urgency & budget in Kit Type.
Economic buyer78 fit
Oligonucleotide-directed Mutagenesis Kits
Strong fit — clear ROI and a fast path to value.
End user65 fit
Enzyme-based Mutagenesis Kits
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Kit Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add End User & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Application
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales47%
Partner / channel27%
Digital / self-serve18%
Marketplaces8%
Positioning & messaging
§GTM 2 · p.194 →For Kit Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Site-directed Mutagenesis Kit Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified45%
Sales qualified25%
Evaluation11%
Closed-won6%
$9.9KCAC
$45KLTV
4.5:1LTV : CAC
< 5 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Site-directed Mutagenesis Kit Market is a resilient opportunity — $2.92B by 2033, compounding at 5.4%.
TAM · 2025$1.92Btoday
TAM · 2033$2.92Bforecast
CAGR5.4%2027–2033
Cumulative$21.5Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$2.92BTotal addressable market
SAM$1.20BServiceable available market
SOM$207MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →5.4% CAGR
Demand compounds through 2033, outpacing GDP across Kit Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Kit Type moving from early to mainstream — durable secular demand.
Consolidation upside
15+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$2.92BLarge & growingTAM by 2033 at 5.4% CAGR
$1.20BServiceable nowreachable with today’s model
$207MBeachhead winobtainable near-term share
15+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$2.28BBear3.5% CAGR
$2.92BBase5.4% CAGR
$3.74BBull7.1% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & End User optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Site-directed Mutagenesis Kit Market — a $1.53B market by 2033. Plan: grow share from 6.3% to 12.4%.
Market size · 2033$1.53Btotal addressable
Market CAGR5.2%2027–2033
Target share12.4%from 6.3% today
Revenue ambition$189Mby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 6.3% | 12.4% | On track |
| Revenue | $104M | $189M | On track |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | Ahead |
| Segment coverage | 2 of 4 axes | 4 of 4 axes | Ahead |
| Gross margin | 31.2% | 41.2% | Behind |
| Customer retention | 88.4% | 93.6% | On track |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Kit Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build End User capability
A defensible second engine — invest in End User to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Kit Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch End User
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $25M capacity & capability investment
- Greenlight bolt-on M&A in End User
- Authorise North America expansion plan
- Fund R&D program for Kit Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownAt risk
- Competitive share lossAt risk
- Input-cost & supply riskOn track
- Regulatory / policy changeBehind
- Execution & talentBehind
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Site-directed Mutagenesis Kit Market conversation — a $1.70B market you can size, segment and defend in minutes.
Market size · 2033$1.70Btotal opportunity
Growth8.8%CAGR to 2033
Addressable buyers1,514+accounts in scope
Typical ROI5.4×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Kit Type
Goal Grow share in Kit Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →5.4×return on cost, year one
< 2 mopayback period
$99K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
15+players profiled in this market
Coverage includes
Thermo Fisher ScientificNew England BiolabsAgilent TechnologiesTakara Bio Inc.QiagenPromega CorporationBio-Rad LaboratoriesSigma-Aldrich (Merck Group)+7 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Site-directed Mutagenesis Kit Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Site-directed Mutagenesis Kit Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →Sitagliptin Tablet Market
Market size, share, segmentation and regional forecast.
$5.0B market · 2025 base year
View reportSitagliptin Phosphate Tablets Market
Market size, share, segmentation and regional forecast.
$6.1B market · 2025 base year
View reportSitagliptin Phosphate Monohydrate Market
Market size, share, segmentation and regional forecast.
$631M market · 2025 base year
View reportSitagliptin Phosphate Market
Market size, share, segmentation and regional forecast.
$3.9B market · 2025 base year
View reportSitagliptin Phosphate API Market
Market size, share, segmentation and regional forecast.
$6.0B market · 2025 base year
View reportSitagliptin Market
Market size, share, segmentation and regional forecast.
$1.9B market · 2025 base year
View reportSitagliptin API Market
Market size, share, segmentation and regional forecast.
$712M market · 2025 base year
View reportSisomicin Sulfate Market
Market size, share, segmentation and regional forecast.
$3.2B market · 2025 base year
View reportSirolimus Eluting Coronary Stent System Market
Market size, share, segmentation and regional forecast.
$3.6B market · 2025 base year
View reportSirolimus Eluting Coronary Stent Market
Market size, share, segmentation and regional forecast.
$4.4B market · 2025 base year
View reportSirolimus API Market
Market size, share, segmentation and regional forecast.
$3.5B market · 2025 base year
View reportsiRNA Drug Market
Market size, share, segmentation and regional forecast.
$1.8B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.